|Previous Section||Index||Home Page|
Tim Loughton: To ask the Secretary of State for Health what discussions her officials have had with the Bounty Company about the extension of its use in hospital for the promotion of health messages. 
Mr. Byrne: Officials held discussions earlier this year with the Bounty Company to explore the possibility of distributing the Department's breastfeeding leaflet in Bounty packs. Following these discussions it was decided not to pursue this idea further.
Tim Loughton: To ask the Secretary of State for Health what assessment she has made of the likely effects on patients in the East Worthing and Shoreham constituency of the proposed transfer of specialist treatment of oesophagal and gastric cancer from Worthing Hospital to Brighton. 
It is the responsibility of the local national health service organisations in conjunction with their cancer networks to plan and develop cancer services, and ensure that existing services comply with national guidelines published by the National Institute for Health and Clinical Excellence.
24 Oct 2005 : Column 166W
Surrey and Sussex Strategic Health Authority has advised that the proposal to transfer the service from Worthing and Southlands Hospitals NHS Trust to Brighton and Sussex University Hospitals NHS Trust was agreed by the Sussex cancer network policy board following extensive work with local NHS organisations and other stakeholders.
I understand that this proposal will enable surgery to be performed in a cancer centre with the support of a full upper gastrointestinal, oesophagal, gastric and pancreatic, cancer multi-disciplinary team.
Mr. Laurence Robertson: To ask the Secretary of State for Health what restrictions exist on (a) the advertising of cures for cancer and (b) the reporting of items relating to cancer; and if she will make a statement. 
No person shall take any part in the publication of any advertisement(a) containing an offer to treat any person for cancer, or to prescribe any remedy therefore, or to give any advice in connection with the treatment thereof".
Dr. Cable: To ask the Secretary of State for Health (1) how many people receiving cancer treatment have been sectioned under the Mental Health Act in each of the last five years for which records are available; 
Psychological distress is common among people affected by cancer. In March 2004, the National Institute for Heath and Clinical Excellence produced guidance on supportive and palliative care for adults with cancer. The guidance sets out recommendations on the provision of psychological support services.
Dr. Cable: To ask the Secretary of State for Health how many cancer treatments have been approved by the National Institute for Health and Clinical Excellence in each of the last five years for which records are available. 
|Ovarian cancertaxanes (No. 3)obsolete, replaced by No. 55||May 2000|
|Breast cancertaxanes (No. 6)obsolete, replaced by No. 30||June 2000|
|Brain cancertemozolomide (No. 23)||April 2001|
|Pancreatic cancergemcitabine (No. 25)||May 2001|
|Lung cancerdocetaxel, paclitaxel, gemcitabine and vinorelbine (No. 26)obsolete, updated by and incorporated into the guideline on the diagnosis and treatment of lung cancer (CG24)||June 2001|
|Ovarian cancertopotecan (No. 28)obsolete, replaced by No. 91||July 2001|
|Leukaemia (lymphocytic)fludarabine (No. 29)||September 2001|
|Breast cancertaxanesreview (No. 30)||September 2001|
|Breast cancertrastuzumab (No. 34)||March 2002|
|Colorectal cancer (advanced)irinotecan, oxaliplatin and raltitrexed (No. 33)||March 2002|
|Lymphoma (follicular non-Hodgkin's)rituximab (No. 37)||March 2002|
|Ovarian cancer (advanced)pegylated liposomal doxorubicin hydrochloride (No. 45)obsolete, replaced by No.91||July 2002|
|Leukaemia (chronic myeloid)imatinib (No. 50) obsolete, replaced by No. 70||October 2002|
|Breast cancervinorelbine (No. 54)||December 2002|
|Ovarian cancerpaclitaxel (review) (No. 55)||January 2003|
|Breast cancercapecitabine (No. 62)||May 2003|
|Colorectal cancercapecitabine and tegafur uracil (No. 61)||May 2003|
|Non-Hodgkin's lymphomarituximab (No. 65)||September 2003|
|Leukaemia (chronic myeloid)imatinib (No. 70)||October 2003|
|Gastro-intestinal stromal tumours (GIST)imatinib (No. 86)||October 2004|
|Ovarian cancer (advanced)paclitaxel, pegylated liposomal doxorubicin hydrochloride and topotecan (review) (No. 91)||May 2005|
|Colorectal cancer (advanced)irinotecan, oxaliplatin and raltitrexed (review) (No. 93)||August 2005|
Mr. Burstow: To ask the Secretary of State for Health what level of expertise and training is required of Commission for Social Care Inspection inspectors on the management of nutrition and dietary care for older people in care homes. 
Mr. Byrne: I understand from the chief executive of the Commission for Social Care Inspection (CSCI), that CSCI has developed guidance for inspectors in consultation with dietary experts, on the management of nutrition and dietary care for older people in care homes.
As part of the continuous professional development for all inspectors, CSCI has established a learning resource centre, which gives inspectors access to a wide range of clinical and professional information. In addition, on a monthly basis specific care issues like the management of nutritional and dietary requirements are focused on, with electronic links provided to websites and articles providing updates on good practice.
Ms Rosie Winterton:
In the last five years there was one prescription issued for platinum based chemotherapy drugs by the national health service. Prescription information is not collected by age and therefore we cannot say if the prescription was for a child.
24 Oct 2005 : Column 168W
|Next Section||Index||Home Page|